Use of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrialsAudit and feedback: An intervention to improve discharge summary completion
Dinescu A, Fernandez H, Ross JS, Karani R. Audit and feedback: An intervention to improve discharge summary completion. Journal Of Hospital Medicine 2011, 6: 28-32. PMID: 21241038, PMCID: PMC3102562, DOI: 10.1002/jhm.831.Peer-Reviewed Original ResearchConceptsDischarge summariesDuration of hospitalizationPost-intervention studyDischarge summary completionFirst-year fellowsImportant clinical informationGeriatric medicine fellowsAdverse eventsDischarge planningOutpatient settingClinical informationYear fellowsGeriatric careIntervention studiesSame checklistFeedback sessionsPerformance scoresPhase 2Feedback interventionPhase 1InterventionIndividual performance scoresAuditChecklistRehospitalization